Study Probes Whether Belimumab Can Lower Vasculitis Relapse Rate

In an international clinical trial, adding the drug belimumab to standard maintenance therapy for patients in remission with vasculitis did not lower the relapse rate. The double-blind, placebo-controlled study evaluated the safety and efficacy of belimumab as adjunctive therapy to maintain remission in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Results of the multi-center, industry-sponsored... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Research Reviews Vasculitis ANCA-Associated Vasculitis anti-neutrophil cytoplasmic antibodies (ANCA) belimumab relapse Remission Source Type: research